IN-VITRO COMPARISON ACTIVITY OF OPC-17116, A NEW FLUOROQUINOLONE, AGAINST MORE THAN 5,000 RECENT CLINICAL ISOLATES FROM 5 MEDICAL-CENTERS

The in vitro activity of OPC 17116, a new fluoroquinolone, was compare d with those of ciprofloxacin, ofloxacin and cefixime. A total of 5,23 1 fresh clinical isolates from five geographically separate US medical centers were tested. The primary results of this study are: 1. OPC-17 116 is very active against Enterobacteriaceae [MIC(90)s, 0.015 - 1 mu g/ml, except Providencia rettgeri (MIC(90)s, >8 mu g/ml)], 2. among no nenteric Gram-negative bacilli (e.g. Xanthomonas maltophilia, MIC(90), 2 mu g/ml) and Gram-positive cocci (e.g. oxacillin susceptible staphy lococci, MIC(90)s, 0.12-0.5 mu g/ml) OPC-17116 demonstrated higher act ivity than ciprofloxacin or ofloxacin, 3. the quinolones were more act ive than cefixime against most of the species tested, especially again st Gram-positive and non-enteric Gram-negative organisms. The results of this study, associated with prior documented favorable qualities, s upport continued investigation of OPC-17116 for clinical use.